MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline ...

Presenting at the annual J.P. Morgan Healthcare Conference on Monday, Moderna said it expects 2025 revenue of roughly $1.9 ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...

Moderna reiterated its plan to deliver up to 10% revenue growth in 2026 while further reducing operating expenses. The ...

Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's ...

Peter Marks, who led the FDA's Center for Biologics Evaluation and Research (CBER), resigned Friday. As the head of CBER, Marks was critical in the rapid approval of COVID-19 vaccines during the ...